ISRCTN55428162已完成未知
A multicentre randomised trial of etanercept and methotrexate to induce remission in early inflammatory arthritis
niversity of Leeds (UK)0 个研究点目标入组 110 人开始时间: 2007年4月30日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 110
研究概览
简要总结
2010 results in: http://www.ncbi.nlm.nih.gov/pubmed/20187135 2014 results in: http://www.ncbi.nlm.nih.gov/pubmed/24618266
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Subject must fulfill all of the following conditions or characteristics in order to be considered for study enrolment or participation:
- •1. Aged 18 to 80 years
- •2. Patients have articular synovitis, within three months of diagnosis (synovitis is defined as the presence soft tissue swelling and at least one of the following two criteria: tenderness or decreased range of motion)
- •3. Either Rheumatoid Factor (RF) antibody (positive) or Anti-Cyclic Citrullinated Peptide (Anti-CCP) antibody (positive) or Shared Epitope (SE) (positive)
- •4. Demonstrates a negative serum pregnancy test at screening if female of childbearing potential. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant. This includes women who are using contraceptives or whose sexual partners are either sterile or using contraceptives. Sexually active women participating in the study must use a medically acceptable form of contraception during the study and for three months after the last dose of study medications. Medically acceptable forms of contraception for women include oral contraception, injectable or implantable methods, intrauterine devices, or properly used barrier contraception
- •5. Agrees to use a medically accepted form of contraception during the study and for three months after the last dose of study drug, if sexually active male. Medically acceptable forms of contraception for males are a properly used barrier contraceptive or sterilisation
- •6. Is capable of understanding and signing an informed consent form
- •7. Is able and willing to self-inject study drug or have a designee who can do so
- •8. Is able and willing to take oral medication
- •9. Is able to store injectable test article at 2°C to 8°C
- •10. Demonstrates a negative tuberculosis screening test
排除标准
- •Subjects with any of the following conditions or characteristics will be excluded from study enrolment:
- •1. Received previous treatment with any Disease Modifying Anti-Rheumatic Drugs (DMARDs)
- •2. Received previous treatment with ETN or other Tumour Necrosis Factor (TNF) antagonist (e.g. a TNF monoclonal antibody or a soluble TNF receptor)
- •3. Previous treatment with Interleukin-1 (IL-1) receptor antagonist
- •4. Chronic arthritis diagnosed before 16 years old
- •5. Received any investigational ?biological? agent within three months of screening visit
- •6. Received treatment with any investigational drug of ?chemical? nature within one month prior to study screening
- •7. Known Human Immunodeficiency Virus (HIV)
- •8. Presence of any contraindication to ETN or MTX
- •9. Has significant concurrent medical diseases including uncompensated congestive heart failure, myocardial infarction within 12 months, unstable angina pectoris, uncontrolled hypertension, severe pulmonary disease, or history of Human Immunodeficiency Virus (HIV) infection, immunodeficiency syndromes, Central Nervous System (CNS) demyelinating events suggestive of multiple sclerosis, renal or gastrointestinal conditions, which in the opinion of the investigator places the subject at an unacceptable risk for participation in the study
- •10. Has cancer or a history of cancer (other than resected cutaneous basal cell carcinoma, and in situ cervical cancer) within five years of entering the screening period
- •11. Current crystal or infective arthritis
- •12. Chronic infection of the upper respiratory tract (e.g., sinusitis), chest (e.g., bronchiectatic lung disease), urinary tract or skin (e.g., paronychia, chronic ulcers, open wounds)
- •13. Any ongoing or active infection or any major episode of infection requiring hospitalisation or treatment with intravenous (IV) antibiotics within the preceding 30 days and/or orally administered antibiotics in the preceding 15 days
- •14. Demonstrates liver function abnormality (Aspartate Transaminase [AST]/Alanine Transaminase [ALT] more than 2 x Upper Limit of Normal [ULN]) or bilirubin more than 51 µmol/L
- •15. Has renal disease (creatinine level more than 133 µmol/L)
- •16. Has leukopaenia (white blood cells less than 3000 x 10^6/L)
- •17. Has thrombocytopaenia (platelets less than 125 x 10^9/L)
- •18. Has a haemoglobin level of less than 9 g/L for males and less than 85 g/L for females
- •19. Is pregnant or breast-feeding
- •20. Joint surgery within preceding two months (at joints to be assessed within this study)
- •21. Received anti-CD4, diphtheria Interleukin-2 (IL-2) fusion protein, anti-Interleukin-6 (anti-IL-6), rituxamab or other immunosuppressive biologic during the last six months before screening, and treatment with such agents more than six months before screening if there are persistent signs of immunosuppression (with a subsequent abnormal absolute T-cell count) at screening visit
- •22. Received any live (attenuated) vaccines within four weeks of screening visit
- •23. Received cyclophosphamide within six months of screening visit
- •24. Any corticosteroids within 28 days prior to screen
研究者
相似试验
已完成
4 期
Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE)Inflammatory ArthritisRheumatoid ArthritisNCT01303874University of Leeds112
已完成
3 期
Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Rheumatoid ArthritisArthritis, RheumatoidNCT00445770Pfizer550
进行中（未招募）
1 期
A multi-centre randomised trial of Etanercept and Methotrexate to induce remission in early inflammatory arthritis resistent to corticosteroid challenge: The EMPIRE trial - EMPIREEUCTR2005-005467-29-GBniversity of Leeds110
已完成
3 期
Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic ArthritisPsoriatic ArthritisNCT02376790Amgen851
已完成
3 期
Study Evaluating Etanercept Treatment of Patients With Ankylosing SpondylitisAnkylosing SpondylitisNCT00421915Wyeth is now a wholly owned subsidiary of Pfizer84